MediNet Group Ltd. (8161) AI Stock Analysis

• Market Cap: HK$24.96M
• Dividend Yield: N/A
• Average Volume (3M): 5.12K
• Price to Earnings (P/E): 3.1
• Beta (1Y): 0.04
• Revenue Growth: -8.48%
• EPS Growth: N/A
• Country: HK
• Employees: 90
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 41,600,000
• 10 Day Avg. Volume: 5,200
• 30 Day Avg. Volume: 5,120
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.20
• Price to Sales (P/S): 0.13
• P/FCF Ratio: 2.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 59 Neutral
• Price Target: HK$0.50 ▼(-18.03% Downside)

The overall stock score is driven by positive technical indicators and attractive valuation, despite mixed financial performance. The company's profitability improvements are promising, but revenue decline and high leverage are significant concerns. Investors should monitor operational cash flow and leverage management closely.

MediNet Group Ltd. Business Overview & Revenue Model

Company Description

MediNet Group Ltd. (8161) is a healthcare services company based in Hong Kong, primarily focused on providing comprehensive medical and healthcare solutions. The company operates in various sectors including healthcare services, medical equipment distribution, and health information technology. MediNet Group offers a range of products and services such as telemedicine solutions, health management services, and medical consultancy, aimed at enhancing patient care and streamlining healthcare delivery.

How the Company Makes Money

MediNet Group generates revenue through multiple streams. The primary source of income comes from its healthcare services, including fees charged for telemedicine consultations and health management services. Additionally, the company earns revenue from the sale and distribution of medical equipment and health-related products. Strategic partnerships with hospitals, clinics, and healthcare providers further enhance its revenue potential by facilitating access to a broader customer base. Furthermore, MediNet may benefit from government contracts and initiatives aimed at improving public health services, contributing to its overall earnings.

MediNet Group Ltd. Financial Statement Overview

Summary

MediNet Group Ltd. shows mixed financial performance. Improved profitability metrics are overshadowed by declining revenue and high leverage, posing significant risks. Cash flow generation is strong, but operational cash flow needs improvement.

Income Statement

The income statement shows mixed results. Gross profit margin improved significantly to 51.85% in 2025 from 16.66% in 2024, indicating better cost management. However, revenue declined by 8.32% in 2025, reflecting potential challenges in market demand or competition. Net profit margin turned positive at 7.58% in 2025, a notable improvement from negative margins in previous years, suggesting enhanced profitability. Despite these improvements, the overall revenue trend is concerning.

Balance Sheet

The balance sheet reveals a high debt-to-equity ratio of 1.56 in 2025, indicating significant leverage and potential financial risk. Return on equity improved dramatically to 69.48% in 2025, reflecting strong profitability relative to equity. However, the equity ratio is low, suggesting a heavy reliance on debt financing. The company's financial stability is a concern due to high leverage.

Cash Flow

The cash flow statement shows a positive trend with a 16.31% growth in free cash flow in 2025, indicating improved cash generation. The operating cash flow to net income ratio is low at 0.14, suggesting limited cash flow relative to net income. However, the free cash flow to net income ratio is strong at 94.29%, indicating efficient cash conversion. Overall, cash flow management appears solid, but there is room for improvement in operational cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	130.65M	106.39M	116.25M	110.39M	121.07M	129.48M
Gross Profit	17.77M	55.16M	15.20M	56.68M	65.44M	70.55M
EBITDA	-417.50K	17.54M	2.39M	-11.60M	8.06M	20.10M
Net Income	12.55M	8.06M	-8.08M	-24.88M	-6.22M	4.75M
Balance Sheet
Total Assets	51.65M	51.65M	42.03M	42.88M	68.46M	75.89M
Cash, Cash Equivalents and Short-Term Investments	13.87M	13.87M	17.32M	15.57M	15.60M	20.65M
Total Debt	18.11M	18.11M	15.96M	9.82M	12.85M	14.25M
Total Liabilities	40.50M	40.50M	38.84M	31.55M	31.82M	32.84M
Stockholders Equity	11.60M	11.60M	3.63M	11.76M	36.80M	43.05M
Cash Flow
Free Cash Flow	4.82M	4.82M	1.61M	9.65M	6.45M	16.55M
Operating Cash Flow	5.11M	5.11M	4.40M	10.36M	7.22M	18.59M
Investing Cash Flow	170.00K	184.00K	-2.59M	-707.00K	-772.00K	-2.40M
Financing Cash Flow	-12.72M	-8.67M	-11.00K	-9.53M	-11.56M	-11.70M

MediNet Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.61
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8161, the sentiment is Positive. The current price of 0.61 is above the 20-day moving average (MA) of 0.61, above the 50-day MA of 0.57, and above the 200-day MA of 0.44, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 53.61 is Neutral, neither overbought nor oversold. The STOCH value of 59.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8161.

MediNet Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2293	75 Outperform	HK$221.35M	12.56	7.84%	4.55%	-21.50%	-43.25%
8161	59 Neutral	HK$24.96M	3.15	105.83%	―	-8.48%	―
8307	59 Neutral	HK$78.55M	―	-44.60%	―	-8.20%	-10.39%
8357	58 Neutral	HK$114.82M	―	-10.31%	―	-11.68%	-71.01%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
8143	51 Neutral	HK$197.28M	―	―	―	-58.63%	40.85%
8437	39 Underperform	HK$11.19M	-0.38	―	―	14.64%	-81.95%